Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.69 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 7/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 7/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.42 |
| ▸ | ESRRA | P11474 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758358 | 1.00 | RXRA (0.69) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL5757584 | 0.87 | RXRA (0.63) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL5791119 | 0.87 | RXRA (0.63) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL304433 | 0.86 | RXRA (0.69) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL304434 | 0.86 | RXRA (0.69) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL1619112 | 0.86 | RXRA (0.69) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL5758159 | 0.86 | RXRA (0.54) | RXRA | |
| SCHEMBL6450433 | 0.84 | RXRA (0.66) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL6450432 | 0.84 | RXRA (0.66) | RXRASCN9APIM1PIM2PDE4B | |
| SCHEMBL5791282 | 0.83 | RXRA (0.81) | RXRASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102000-B2 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1487443-A4 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-12 | — | — | EP | claimed |
| EP-1487443-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2004-12-22 | — | — | EP | claimed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003075924-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | claimed |
| US-20060241138-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | PFAHL MAGNUS | 2006-10-26 | — | — | US | disclosed |
| US-7102000-B2 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | INCYTE SAN DIEGO INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1487443-A4 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1487443-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | Incyte San Diego Incorporated (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | ORTHO MCNEIL PHARMACEUTICAL INC. | 2003-11-20 | — | — | US | disclosed |
| WO-2003075924-A1 | HETEROCYCLIC AMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES AND OTHER DISEASES | INCYTE SAN DIEGO INCORPORATED (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241138-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | HDAC5, KAT5, IGFBP5 | RXRA 829/4885SCN9A 2067/4885PIM1 2354/4885 |
| US-20030216432-A1 | Heterocyclic amide derivatives for the treatment of diabetes and other diseases | GCKR, HDAC5, GPR119 | RXRA 955/4885SCN9A 2999/4885PIM1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.